Under the clinical trial, randomized and blinded study aims to determine the optimal dosage of both VE Patch and the H5N1 influenza vaccine injected concomitantly, when combined with each other in a single dose regimen.
Thomas Lingelbach, COO of Intercell AG and CEO of Intercell USA, said: the commencement of this Phase II study represents an important milestone in the clinical development of our VE Patch technology and in the partnership with HHS for use of our technology in providing potentially improved Pandemic Influenza vaccines.
The recent H1N1 influenza situation certainly highlights again the important global public health need in this arena. If we achieve our goal to achieve full protection with only a single dose plus patch this means an enormous logistical advantage making PanFlu immunization feasible, he added.